nydrane Report issue

Small molecule Experimental
ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

Beclamide (N-benzyl-B-chloropropionamide) is a drug that possesses anticonvulsant activity. It is no longer used. It has been used as a sedative and as an anticonvulsant. Beclamide has been used in the management of both epilepsy and behavioral disorders associated with epilepsy. It was introduced into clinical practice in 1952 under the brand names Hibicon, Lederle and later it was withdrawn. This agent was shown to be effective in grand mal but not absence seizures. Early claims emphasized its safety, and it is not entirely clear why it was withdrawn from therapy for epilepsy. Interest in the drug was rekindled in the 1990s as an adjunct in the treatment of schizophrenia.   NCATS

Chemistry

  • SMILES: ClCCC(=O)NCC1=CC=CC=C1
  • InChIKey: JPYQFYIEOUVJDU-UHFFFAOYSA-N
  • Mol. Mass: 197.661
  • ALogP: 1.93
  • ChEMBL Molecule:
    beclamide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

beclamid | beclamide | beklamid | benzchlorpropamide | benzylamide | chloracon | chlorakon | chloroethylphenamide | n-benzyl-3-chloropropionamide | neuracen | nidrane | nydran | nydrane | posedrine

Indications (2)

Approved Indications (1)


 

Epilepsy (approved 1952)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Schizophrenia (Phase 1)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue